Press releases
- Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
- Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
- Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
- Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
- Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
- Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
- Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
More ▼
Key statistics
As of last trade Citius Pharmaceuticals Inc (47N:FRA) traded at 0.8315, -19.11% below its 52-week high of 1.03, set on Jul 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.8315 |
---|---|
High | 0.8315 |
Low | 0.8315 |
Bid | 0.8665 |
Offer | 0.9005 |
Previous close | 0.765 |
Average volume | 3.86k |
---|---|
Shares outstanding | 180.67m |
Free float | 168.37m |
P/E (TTM) | -- |
Market cap | 168.04m USD |
EPS (TTM) | -0.2367 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 07:06 BST.
More ▼